Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kakolyris

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2000
c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancerM I Koukourakis, A Giatromanolaki, F Guddo, et al.
Lung Cancer (Amsterdam, Netherlands)|September 29, 2009
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II studyN Xenidis, A Kotsakis, A Kalykaki, et al.
Oncology|June 12, 2008
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II studyS Kakolyris, J Souglakos, A Polyzos, et al.
Mutation Research|June 16, 2015
Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patientsI Balgkouranidou, D Matthaios, A Karayiannakis, et al.
British Journal of Cancer|March 25, 2000
Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39S Kakolyris, S B Fox, M Koukourakis, et al.
Anticancer Research|July 1, 1997
P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expressionC Kouvidou, K Stefanaki, Y Dai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2003
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumorsD Mavroudis, P Pappas, C Kouroussis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II studyN Androulakis, C Kourousis, M A Dimopoulos, et al.
Anticancer Research|September 1, 1996
Expression of p53 and mdm-2 proteins in Hodgkin's Disease. Absence of correlation with the presence of Epstein-Barr virusM Tzardi, C Kouvidou, I Panayiotides, et al.
Lung Cancer (Amsterdam, Netherlands)|May 27, 2008
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapyA G Pallis, S Agelaki, S Kakolyris, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2000
c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancerM I Koukourakis, A Giatromanolaki, F Guddo, et al.
Lung Cancer (Amsterdam, Netherlands)|September 29, 2009
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II studyN Xenidis, A Kotsakis, A Kalykaki, et al.
Oncology|June 12, 2008
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II studyS Kakolyris, J Souglakos, A Polyzos, et al.
Mutation Research|June 16, 2015
Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patientsI Balgkouranidou, D Matthaios, A Karayiannakis, et al.
British Journal of Cancer|March 25, 2000
Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39S Kakolyris, S B Fox, M Koukourakis, et al.
Anticancer Research|July 1, 1997
P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expressionC Kouvidou, K Stefanaki, Y Dai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2003
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumorsD Mavroudis, P Pappas, C Kouroussis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II studyN Androulakis, C Kourousis, M A Dimopoulos, et al.
Anticancer Research|September 1, 1996
Expression of p53 and mdm-2 proteins in Hodgkin's Disease. Absence of correlation with the presence of Epstein-Barr virusM Tzardi, C Kouvidou, I Panayiotides, et al.
Lung Cancer (Amsterdam, Netherlands)|May 27, 2008
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapyA G Pallis, S Agelaki, S Kakolyris, et al.
Pageof 13